MedAdvisor Limited has received a non-binding offer from a major multinational software company to acquire its ANZ business division, valuing it above current market expectations.
MedAdvisor Limited’s trading suspension has been lifted immediately following the release of an announcement about the outcome of a court application under the Corporations Act 2001.
MedAdvisor Solutions reported a challenging third quarter with steep revenue declines, driven by delayed program launches and US sales underperformance, but is executing a strategic overhaul and cost-cutting measures to position for a rebound and 15% revenue growth in FY26.
MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.
MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.